Generation Bio’s (GBIO) Outperform Rating Reiterated at Wedbush

Wedbush restated their outperform rating on shares of Generation Bio (NASDAQ:GBIO) in a report released on Friday morning,RTT News reports. Wedbush currently has a $5.00 target price on the stock.

Separately, Needham & Company LLC reissued a “buy” rating and set a $8.00 target price on shares of Generation Bio in a research note on Friday.

Generation Bio Stock Performance

Generation Bio stock opened at $0.48 on Friday. The company has a 50 day moving average price of $0.74 and a 200 day moving average price of $1.51. Generation Bio has a 52 week low of $0.47 and a 52 week high of $4.65. The firm has a market capitalization of $32.06 million, a price-to-earnings ratio of -0.22 and a beta of 2.72.

Generation Bio (NASDAQ:GBIO) last issued its earnings results on Wednesday, March 19th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.01). The company had revenue of $4.19 million for the quarter, compared to analyst estimates of $2.92 million. Generation Bio had a negative net margin of 782.86% and a negative return on equity of 104.85%. Equities analysts forecast that Generation Bio will post -1.75 earnings per share for the current fiscal year.

Insider Buying and Selling at Generation Bio

In other Generation Bio news, Director Anthony G. Quinn acquired 125,791 shares of Generation Bio stock in a transaction that occurred on Friday, January 10th. The stock was acquired at an average price of $0.96 per share, with a total value of $120,759.36. Following the purchase, the director now owns 214,286 shares in the company, valued at approximately $205,714.56. This trade represents a 142.14 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 21.10% of the company’s stock.

Institutional Investors Weigh In On Generation Bio

Institutional investors and hedge funds have recently modified their holdings of the business. Intech Investment Management LLC acquired a new stake in shares of Generation Bio in the 4th quarter valued at $25,000. Squarepoint Ops LLC acquired a new stake in shares of Generation Bio in the 4th quarter valued at $70,000. Integrated Wealth Concepts LLC acquired a new stake in shares of Generation Bio in the 4th quarter valued at $77,000. Barclays PLC raised its holdings in Generation Bio by 165.5% in the 3rd quarter. Barclays PLC now owns 76,430 shares of the company’s stock worth $189,000 after acquiring an additional 47,639 shares during the period. Finally, Aegis Wealth Management LLC bought a new position in Generation Bio in the 4th quarter worth $94,000. Institutional investors and hedge funds own 95.22% of the company’s stock.

Generation Bio Company Profile

Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.